Dr. Steven Quay featured in Unfiltered by Dan Bongino

In this segment of “Unfiltered,” Dr. Stephen Quay discusses the discovery of remnants of the Nipa virus in the Wuhan Institute of Virology, suggesting potential safety breaches and raising concerns about the lab’s handling of highly lethal viruses. The Nipa virus, originating from bats and affecting the brain with a lethality rate ranging from 50% to 80%, poses significant risks if mishandled. Dr. Quay highlights the lab’s violation of safety protocols, as it was not equipped for the level of biosecurity required for such dangerous pathogens. The revelation prompts questions about whether the lab was conducting gain-of-function research to enhance the virus’s potency. Overall, the discussion underscores the alarming implications of such discoveries for global health security.

Steven Quay is the founder of Seattle-based Atossa Therapeutics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions.

He received his M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital, and was on the faculty of Stanford University School of Medicine. His contributions to medicine have been cited over 9,600 times. He has founded six startups, invented seven FDA-approved pharmaceuticals, and holds 87 US patents. Over 80 million people have benefited from the medicines he invented.

His current passion is the prevention of the two million yearly breast cancer cases worldwide.

Related Content

(Z)-Endoxifen Shown to Significantly Reduce Mammographic Breast Density, Potentially Paving the Way for Innovative Cancer Prevention Strategies